epaxal
Vaccineexperimental
Hepatitis A vaccine is a vaccine that prevents hepatitis A. It is effective in around 95% of cases and lasts for at least twenty years and possibly a person's entire life. If given, two doses are recommended beginning after the age of one. It is given by injection into a muscle. The first hepatitis A vaccine was approved in the European Union in 1991, and the United States in 1995. It is on the World Health Organization's List of Essential Medicines. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Jun 1, 2004 (NCT01405677)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Hepatitis A virusImmunity, active
Hepatitis A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHepatitis A vaccine ↗
Also known as
- epaxal
- epaxal
- epaxal berna
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01341808 | Phase 4 | Apr 1, 2011 | University of Ulsan |
| NCT01405677 | Phase 2 | Jun 1, 2004 | Crucell, University of Antwerp, University of Freiburg |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crucell | For profit | 1 | 1 | 1 | 2004 |
| University of Antwerp | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Freiburg | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2011 |
4 organizations
Page 1 / 1